Applied Biosystems, Inc. (formerly NASDAQ: ABIO) started as GeneCo (Genetic Systems Company), was the name of a pioneer biotechnology company founded in 1981 in Foster City, California, in the San Francisco Bay Area.[1] Through the 1980s and early 1990s it operated independently and manufactured biochemicals and automated genetic engineering and diagnostic research instruments, including the principal brand of DNA sequencing machine used by the Human Genome Project consortium centers. Applied Biosystems' close ties to the consortium project led to the idea for the founding of Celera Genomics (NYSE: CRA) in 1998 as one of several independent competitors to the consortium.[2]
In 1983 Applied Biosystems was delisted from the NASDAQ when it was acquired by the old company known then as Perkin-Elmer (formerly NYSE: PKN). As the PE Applied Biosystems Division under that parent in 1998, it became consolidated with other acquisitions as the primary PE Biosystems Division. In 1999 its parent company reorganized and changed its name to PE Corporation, and the PE Biosystems Group (formerly NYSE: PEB) again became publicly traded, as a tracking stock of its parent, along with its sister tracking stock company, Celera Genomics. In 2000 the parent became Applera Corporation. The Applied Biosystems name also returned that year, in the name change of the tracking stock from PE Biosystems Group to Applera Corporation-Applied Biosystems Group (NYSE: ABI), an S&P 500 company, which remains as a publicly-traded operating group within Applera Corp., along with its sibling operating group, Applera Corporation-Celera Group. Applera derives its name from the combination of its two component groups' names, Appl(iedCel)era.[3] In November 2008, a merger between Applied Biosystems and Invitrogen [4] was finalized "creating a global leader in biotechnology reagents and systems". The new company is called Life Technologies.
In May 1981, the company was founded by two scientist/engineer from Hewlett Packard, Sam Eletr. and Andre Marion[1]
In August 1982, Applied Biosystems released its first commercial instrument, the Model 470A Protein Sequencer. The machine enabled scientists to determine the order of amino acids within a purified protein, which in turn correlated with the protein's function. With 40 employees, the company, reported first-time revenue of US$402,000.[1]
In 1983 the company was led by its president and Chairman of the Board, Sam Eletr and Chief Operating Officer Andre Marion, the company doubled its number of employees to 80, and its stock went public on the NASDAQ exchange under the symbol ABIO, with revenues of US$5.9 million. A new product was a fluorescent molecular tag for immunodiagnostic assays.[1]
The company released its second commercial instrument, the Model 380A DNA Synthesizer, which made oligonucleotides, short DNA strands, for polymerase chain reaction (PCR), DNA sequencing, and gene identification. The two sequencer and synthesizer products allowed molecular biologists to clone genes by building oligonucleotides with the desired protein's DNA sequence.[1]
Automated DNA sequencing began at the California Institute of Technology, using fluorescent dyes, with Rights to the technology granted to Applied Biosystems.[1] At CIT, Dr. Leroy Hood and Dr. Lloyd Smith, together pioneered those first DNA sequencing machines.[2]
In 1984, Applied Biosystems sales revenue tripled to over US$18 million, with a second yearly profit, and with over 200 employees. Services included synthesizing custom DNA and protein fragments, and the sequencing of protein samples submitted from customers. The third major instrument made by Applied, the Model 430A Peptide Synthesizer, was introduced.[1]
In 1985, Applied Biosystems sales revenue grew nearly 70% to over US$35 million, with a third yearly profit. Two new products included the Model 380B DNA Synthesizer and the 381A DNA Synthesizer. That year the company went international for the first time, when it established a wholly-owned subsidiary in Great Britain to save shipping costs on chemical sales, which overall by then accounted for 17% of sales.[1]
Also in 1985, Applied Biosystems acquired Brownlee Labs, a manufacturer of columns and pumps for high performance liquid chromatography (HPLC) systems, after its founder, Robert Brownlee was diagnosed with AIDS-related complex in 1984.[5] Brownlee's technology brought the new on-line 120A PTH Amino Acid Analyzer.[1]
However, Brownlee then began a new company, which was viewed by Applied as a competitor. In 1989 Applied and Brownlee settled in a lawsuit over the conflict.[6] As late as 1990, Brownlee publicly discussed what had been his contributions in the rocky relationship with Applied, before he died early the next year.
Applied Biosystems, Inc. (formerly NASDAQ: ABIO) started as GeneCo (Genetic Systems Company), was the name of a pioneer biotechnology company founded in 1981 in Foster City, California, in the San Francisco Bay Area.[1] Through the 1980s and early 1990s it operated independently and manufactured biochemicals and automated genetic engineering and diagnostic research instruments, including the principal brand of DNA sequencing machine used by the Human Genome Project consortium centers. Applied Biosystems' close ties to the consortium project led to the idea for the founding of Celera Genomics (NYSE: CRA) in 1998 as one of several independent competitors to the consortium.[2]
In 1983 Applied Biosystems was delisted from the NASDAQ when it was acquired by the old company known then as Perkin-Elmer (formerly NYSE: PKN). As the PE Applied Biosystems Division under that parent in 1998, it became consolidated with other acquisitions as the primary PE Biosystems Division. In 1999 its parent company reorganized and changed its name to PE Corporation, and the PE Biosystems Group (formerly NYSE: PEB) again became publicly traded, as a tracking stock of its parent, along with its sister tracking stock company, Celera Genomics. In 2000 the parent became Applera Corporation. The Applied Biosystems name also returned that year, in the name change of the tracking stock from PE Biosystems Group to Applera Corporation-Applied Biosystems Group (NYSE: ABI), an S&P 500 company, which remains as a publicly-traded operating group within Applera Corp., along with its sibling operating group, Applera Corporation-Celera Group. Applera derives its name from the combination of its two component groups' names, Appl(iedCel)era.[3] In November 2008, a merger between Applied Biosystems and Invitrogen [4] was finalized "creating a global leader in biotechnology reagents and systems". The new company is called Life Technologies.
New SEC
Filings for ABIO Commentary
for ABIO Price
Charts Company
Financials
Last Sale $ 2.38
Change Net / % 0.01 0.42%
Best Bid / Ask N/A / N/A
1y Target Est: N/A
Today's High / Low $ 2.56 / $ 2.25
Share Volume 91,123
50 Day Avg. Daily Volume N/A
Previous Close $ 2.39
52 Wk High / Low $ 6.23 / $ 2.34
Shares Outstanding 8,835,000
Market Value of Listed Security $ 21,027,300
P/E Ratio NE
Forward P/E (1yr) N/A
Earnings Per Share $ -1.68
Annualized Dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield N/A
Beta 0.45
NASDAQ Official Open Price: $ 2.41
Date of NASDAQ Official Open Price: Mar. 30, 2011
NASDAQ Official Close Price: $ 2.36
Date of NASDAQ Official Close Price: Mar. 30, 2011
Community Sentiment Not yet rated, rate it now
Intraday Chart
5d | 1m | 6m | 12m | More Charting
Company News for ABIO Subscribe
CEO of ARCA biopharma to Speak on Cardiovascular Implications of Personalized Medicine at Personalized Medicine Coalition Conference on January 6, 2011
- Business Wire 01/05/2011 8:00AM
Competitive Technologies: Short Squeeze Coming or Another Leg Down?
- Seeking Alpha 08/25/2010 9:12AM
Drug Pipeline Pulse Check: A Challenging Week
- Seeking Alpha 03/30/2010 3:28PM
Read more ABIO News & Commentary
Company Description (as filed with the SEC)
ARCA biopharma, Inc. (the "Company" or "ARCA"), a Delaware corporation, is headquartered in Broomfield, Colorado and is principally focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator for chronic heart failure, or HF. Gencaro was the subject of a Phase 3 heart failure mortality trial involving more than 2,700 patients and was unique in gathering DNA data on over 1,000 of its participants. The Company has licensed exclusive, worldwide rights to Gencaro. In September 2008, the U.S. Food and Drug Administration ("FDA") accepted for filing the Company’s New Drug Application ("NDA") for Gencaro. On May 29, 2009, the FDA issued a Complete Response Letter to the Company which stated that the FDA could not approve the Gencaro NDA in its current form and specified additional actions and information required by the FDA for approval of the NDA.
In 1983 Applied Biosystems was delisted from the NASDAQ when it was acquired by the old company known then as Perkin-Elmer (formerly NYSE: PKN). As the PE Applied Biosystems Division under that parent in 1998, it became consolidated with other acquisitions as the primary PE Biosystems Division. In 1999 its parent company reorganized and changed its name to PE Corporation, and the PE Biosystems Group (formerly NYSE: PEB) again became publicly traded, as a tracking stock of its parent, along with its sister tracking stock company, Celera Genomics. In 2000 the parent became Applera Corporation. The Applied Biosystems name also returned that year, in the name change of the tracking stock from PE Biosystems Group to Applera Corporation-Applied Biosystems Group (NYSE: ABI), an S&P 500 company, which remains as a publicly-traded operating group within Applera Corp., along with its sibling operating group, Applera Corporation-Celera Group. Applera derives its name from the combination of its two component groups' names, Appl(iedCel)era.[3] In November 2008, a merger between Applied Biosystems and Invitrogen [4] was finalized "creating a global leader in biotechnology reagents and systems". The new company is called Life Technologies.
In May 1981, the company was founded by two scientist/engineer from Hewlett Packard, Sam Eletr. and Andre Marion[1]
In August 1982, Applied Biosystems released its first commercial instrument, the Model 470A Protein Sequencer. The machine enabled scientists to determine the order of amino acids within a purified protein, which in turn correlated with the protein's function. With 40 employees, the company, reported first-time revenue of US$402,000.[1]
In 1983 the company was led by its president and Chairman of the Board, Sam Eletr and Chief Operating Officer Andre Marion, the company doubled its number of employees to 80, and its stock went public on the NASDAQ exchange under the symbol ABIO, with revenues of US$5.9 million. A new product was a fluorescent molecular tag for immunodiagnostic assays.[1]
The company released its second commercial instrument, the Model 380A DNA Synthesizer, which made oligonucleotides, short DNA strands, for polymerase chain reaction (PCR), DNA sequencing, and gene identification. The two sequencer and synthesizer products allowed molecular biologists to clone genes by building oligonucleotides with the desired protein's DNA sequence.[1]
Automated DNA sequencing began at the California Institute of Technology, using fluorescent dyes, with Rights to the technology granted to Applied Biosystems.[1] At CIT, Dr. Leroy Hood and Dr. Lloyd Smith, together pioneered those first DNA sequencing machines.[2]
In 1984, Applied Biosystems sales revenue tripled to over US$18 million, with a second yearly profit, and with over 200 employees. Services included synthesizing custom DNA and protein fragments, and the sequencing of protein samples submitted from customers. The third major instrument made by Applied, the Model 430A Peptide Synthesizer, was introduced.[1]
In 1985, Applied Biosystems sales revenue grew nearly 70% to over US$35 million, with a third yearly profit. Two new products included the Model 380B DNA Synthesizer and the 381A DNA Synthesizer. That year the company went international for the first time, when it established a wholly-owned subsidiary in Great Britain to save shipping costs on chemical sales, which overall by then accounted for 17% of sales.[1]
Also in 1985, Applied Biosystems acquired Brownlee Labs, a manufacturer of columns and pumps for high performance liquid chromatography (HPLC) systems, after its founder, Robert Brownlee was diagnosed with AIDS-related complex in 1984.[5] Brownlee's technology brought the new on-line 120A PTH Amino Acid Analyzer.[1]
However, Brownlee then began a new company, which was viewed by Applied as a competitor. In 1989 Applied and Brownlee settled in a lawsuit over the conflict.[6] As late as 1990, Brownlee publicly discussed what had been his contributions in the rocky relationship with Applied, before he died early the next year.
Applied Biosystems, Inc. (formerly NASDAQ: ABIO) started as GeneCo (Genetic Systems Company), was the name of a pioneer biotechnology company founded in 1981 in Foster City, California, in the San Francisco Bay Area.[1] Through the 1980s and early 1990s it operated independently and manufactured biochemicals and automated genetic engineering and diagnostic research instruments, including the principal brand of DNA sequencing machine used by the Human Genome Project consortium centers. Applied Biosystems' close ties to the consortium project led to the idea for the founding of Celera Genomics (NYSE: CRA) in 1998 as one of several independent competitors to the consortium.[2]
In 1983 Applied Biosystems was delisted from the NASDAQ when it was acquired by the old company known then as Perkin-Elmer (formerly NYSE: PKN). As the PE Applied Biosystems Division under that parent in 1998, it became consolidated with other acquisitions as the primary PE Biosystems Division. In 1999 its parent company reorganized and changed its name to PE Corporation, and the PE Biosystems Group (formerly NYSE: PEB) again became publicly traded, as a tracking stock of its parent, along with its sister tracking stock company, Celera Genomics. In 2000 the parent became Applera Corporation. The Applied Biosystems name also returned that year, in the name change of the tracking stock from PE Biosystems Group to Applera Corporation-Applied Biosystems Group (NYSE: ABI), an S&P 500 company, which remains as a publicly-traded operating group within Applera Corp., along with its sibling operating group, Applera Corporation-Celera Group. Applera derives its name from the combination of its two component groups' names, Appl(iedCel)era.[3] In November 2008, a merger between Applied Biosystems and Invitrogen [4] was finalized "creating a global leader in biotechnology reagents and systems". The new company is called Life Technologies.
New SEC
Filings for ABIO Commentary
for ABIO Price
Charts Company
Financials
Last Sale $ 2.38
Change Net / % 0.01 0.42%
Best Bid / Ask N/A / N/A
1y Target Est: N/A
Today's High / Low $ 2.56 / $ 2.25
Share Volume 91,123
50 Day Avg. Daily Volume N/A
Previous Close $ 2.39
52 Wk High / Low $ 6.23 / $ 2.34
Shares Outstanding 8,835,000
Market Value of Listed Security $ 21,027,300
P/E Ratio NE
Forward P/E (1yr) N/A
Earnings Per Share $ -1.68
Annualized Dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield N/A
Beta 0.45
NASDAQ Official Open Price: $ 2.41
Date of NASDAQ Official Open Price: Mar. 30, 2011
NASDAQ Official Close Price: $ 2.36
Date of NASDAQ Official Close Price: Mar. 30, 2011
Community Sentiment Not yet rated, rate it now
Intraday Chart
5d | 1m | 6m | 12m | More Charting
Company News for ABIO Subscribe
CEO of ARCA biopharma to Speak on Cardiovascular Implications of Personalized Medicine at Personalized Medicine Coalition Conference on January 6, 2011
- Business Wire 01/05/2011 8:00AM
Competitive Technologies: Short Squeeze Coming or Another Leg Down?
- Seeking Alpha 08/25/2010 9:12AM
Drug Pipeline Pulse Check: A Challenging Week
- Seeking Alpha 03/30/2010 3:28PM
Read more ABIO News & Commentary
Company Description (as filed with the SEC)
ARCA biopharma, Inc. (the "Company" or "ARCA"), a Delaware corporation, is headquartered in Broomfield, Colorado and is principally focused on developing genetically-targeted therapies for heart failure and other cardiovascular diseases. The Company's lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically unique beta-blocker and mild vasodilator for chronic heart failure, or HF. Gencaro was the subject of a Phase 3 heart failure mortality trial involving more than 2,700 patients and was unique in gathering DNA data on over 1,000 of its participants. The Company has licensed exclusive, worldwide rights to Gencaro. In September 2008, the U.S. Food and Drug Administration ("FDA") accepted for filing the Company’s New Drug Application ("NDA") for Gencaro. On May 29, 2009, the FDA issued a Complete Response Letter to the Company which stated that the FDA could not approve the Gencaro NDA in its current form and specified additional actions and information required by the FDA for approval of the NDA.